

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-naïve and Treatment-experienced Adult Rheumatoid Arthritis Patients

Supplementary Material

Running title: Adherence and drug survival of advance therapies in RA: Real-world study

Vered Rosenberg¹

Gabriel Chodick^{1,2}

Zhenyi Xue³

Freddy Faccin³

Howard Amital^{2,4}

¹Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel

²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

³AbbVie Inc., North Chicago, IL, United States

⁴Department of Medicine 'B' & Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

Corresponding Author: Professor Howard Amital, Department of Medicine 'B' & Zabludowicz Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel. Email: Howard.Amital@sheba.health.gov.il

ORCID iDs:

Vered Rosenberg: 0000-0002-1535-7091

Gabriel Chodick: 0000-0002-5189-8995

Freddy Faccin: 0000-0002-3535-7152

Howard Amital: 0000-0002-5406-7716

Table S1. Mode of administration and dosing schedule by drug

	Mode of administration	Injection administration mode	Dosing schedule
Golimumab	Injection	SC	Every 4-11 weeks
Adalimumab			Every 1-2 weeks
Etanercept			
Certolizumab			
Sarilumab			
Tocilizumab			SC/IV
Abatacept		Every 4-11 weeks (IV)	
Infliximab		IV	Every 4-11 weeks
Rituximab			Every \geq 12 weeks
Tofacitinib	Oral	NA	Daily

IV, intravenous; SC, subcutaneous